Oncotelic Therapeutics (OTCQB: OTLC) announced that its proprietary PDAOAI drug discovery and development platform will be featured during the Product & Engineering keynote at Qdrant Vector Space Day 2026 in San Francisco on June 11. Company executives will join Qdrant leadership to discuss how PDAOAI, operating on Qdrant infrastructure, has helped accelerate the development of two drug candidates from concept to investigational new drug filings in less than two years, significantly reducing the time and cost traditionally associated with pharmaceutical development.
The presentation will highlight several innovations underpinning the platform, including a proprietary 'manifold folding' technique designed to improve semantic retrieval accuracy and reduce large language model hallucinations, as well as the indexing of approximately 28 million PubMed biomedical abstracts on Qdrant Cloud. Oncotelic said the platform leverages advanced vector search technologies to support large-scale biomedical research and accelerate oncology drug discovery efforts. For more details, see the full press release at https://ibn.fm/Ce72F.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products addressing high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The company also leverages its proprietary AI-enabled PDAOAI platform for research, biomarker discovery, and regulatory processes. Beyond internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures, including a 45% interest in GMP Bio. For the latest news and updates, visit the company’s newsroom at https://ibn.fm/OTLC. This event underscores the growing importance of AI in pharmaceutical R&D, potentially transforming how drugs are discovered and brought to market.
